Titan Pharmaceuticals Confirms Meeting With U.S. Food and Drug Administration
Opioid Addiction Treatment: Titan Pharmaceuticals Confirms Meeting With U.S. Food and Drug Administration
"This is an important meeting with the FDA to review all of the information on Probuphine development, especially the robust Phase 3 clinical results of Probuphine in the treatment of opioid addiction. We also expect to discuss and reach agreement with …
Read more on MarketWatch (press release)
Opioid Addiction Treatment: Nursing Management with Buprenorphine Course Introduction
This is a course on opioid addiction and buprenorphine treatment created specifically for nurses. The course includes six one- hour modules covering a variety of topics, such as: Legislative changes regarding Office-Based Opioid Addiction Treatment; The Pharmacology, Effectiveness, and Safety of Buprenorphine; Patient Assessment and Suitability; Clinical Management Issues; Addiction Treatment Issues; and Nurse-Physician Collaboration.
Video Rating: 5 / 5
Related Opioid Addiction Treatment Information…